CSPC Innovation announced that its holding subsidiary Jushi Biotech recently launched a phase IB/II clinical trial of SYS6090 injection combined with advanced or metastatic colorectal cancer. This product is a class 1 recombinant all-human anti-PD-1 fusion of IL-15 protein. Currently, the recruitment and screening of participants is being actively promoted.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.